Show simple item record

dc.contributor.authorJalali, Ren_US
dc.contributor.authorLoughrey, Cen_US
dc.contributor.authorBaumert, Ben_US
dc.contributor.authorPerks, Jen_US
dc.contributor.authorWarrington, APen_US
dc.contributor.authorTraish, Den_US
dc.contributor.authorAshley, Sen_US
dc.contributor.authorBrada, Men_US
dc.date.accessioned2018-09-18T14:41:54Z
dc.date.issued2002en_US
dc.identifier2en_US
dc.identifier.citationClinical Oncology, 2002, 14 pp. 103 - 109en_US
dc.identifier.issn0936-6555en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2794
dc.identifier.doi10.1053/clon.2001.0040en_US
dc.description.abstractABSTRACT: OBJECTIVE: To present early clinical results of stereotactic conformal radiotherapy (SCRT) in patients with benign predominantly skull base meningiomas. MATERIAL AND METHODS: Between August 1994 and August 1999, 41 patients with benign residual or recurrent meningiomas were treated with SCRT. Thirty-three were histologically verified. All patients were immobilized in a GTC stereotactic relocatable frame, and underwent a post-contrast CT localization scan with additional MRI for fusion in 15 patients. Treatment was delivered on a 6MV linear accelerator using three (12 patients), or 4 (29 patients) non-coplanar conformal fixed fields to doses of 50–55Gy in 30–33 daily fractions. Tumours were relatively large with a median gross tumour volume (GTV) of 17.9cm3 (range 2.5–183cm3). RESULTS: At a median follow-up of 21 months (range 6–62 months) none of 41 patients have recurred. The current imaging tumour control rate is 100% at 1 and 3 years. The actuarial survival at 2 years is 100% and 91% at 3 and 5 years. Following SCRT tumour decreased in size in 9 patients. SCRT was well tolerated. Five patients had improvement in vision, and six patients improvement in cranial nerve function. Two patients whose planning target volume (PTV) included the sella developed hypopituitarism during and at 18 months after SCRT. One patient with pre-existing hydrocephalus due to pineal region meningioma developed cognitive impairment 7 months after treatment. One patient with involvement of the optic nerve had visual deterioration at 18 months. CONCLUSIONS: SCRT is a feasible high precision irradiation technique for residual and recurrent skull base meningiomas including both small and larger tumours with excellent early tumour control and low toxicity. Longer follow-up is necessary to demonstrate sustained tumour control and low morbidity of such high precision localized method of fractionated irradiation.en_US
dc.format.extent103 - 109en_US
dc.titleHigh Precision Focused Irradiation in the Form of Fractionated Stereotactic Conformal Radiotherapy (SCRT) for Benign Meningiomas Predominantly in the Skull Base Locationen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1053/clon.2001.0040en_US
rioxxterms.licenseref.startdate2002en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClinical Oncologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.volume14en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Brada)en_US
dc.contributor.icrauthorBrada, Michaelen_US
dc.contributor.icrauthorWarrington,en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record